Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function
- PMID: 12773167
- DOI: 10.1042/bst0310615
Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function
Abstract
The arylamine N-acetyltransferases (NATs) are a unique family of enzymes that catalyse the transfer of an acetyl group from acetyl-CoA to the terminal nitrogen of hydrazine and arylamine drugs and carcinogens. The NATs have been shown to be important in drug detoxification and carcinogen activation, with humans possessing two isoenzymes encoded by polymorphic genes. This polymorphism has pharmacogenetic implications, leading to different rates of inactivation of drugs, including the anti-tubercular agent isoniazid and the anti-hypertensive drug hydralazine. Mice provide a good model for human NAT, allowing genetic manipulation of expression to explore possible endogenous roles of these enzymes. The first three-dimensional NAT structure was resolved for NAT from Salmonella typhimurium, and subsequently the structure of NAT from Mycobacterium smegmatis has been elucidated. These identified a 'Cys-His-Asp' catalytic triad (conserved in all NATs), which is believed to be responsible for the activation of the active site cysteine residue. As more genomic data become available, NAT homologues continue to be found in prokaryotic species, many of which are pathogenic, including Mycobacterium tuberculosis. The discovery of NAT in M. tuberculosis is particularly significant, since this enzyme participates in inactivation of isoniazid in the bacterium, with implications for isoniazid resistance. Structural studies on NAT proteins and phenotypic analyses of organisms (both mice and prokaryotes) following genetic modifications of the nat genes are leading to an understanding of the potentially diverse roles of NAT in endogenous and xenobiotic metabolism. These studies have indicated that NAT, particularly in Mycobacteria, has the potential to be a drug target. Combinatorial chemical approaches, together with in silico structural studies, will allow for advances in the identification of NAT substrates and inhibitors, both as experimental tools and as potential drugs.
Similar articles
-
Arylamine N-acetyltransferases: from structure to function.Drug Metab Rev. 2008;40(3):479-510. doi: 10.1080/03602530802186603. Drug Metab Rev. 2008. PMID: 18642144 Review.
-
Arylamine N-acetyltransferases - of mice, men and microorganisms.Trends Pharmacol Sci. 2001 Mar;22(3):140-6. doi: 10.1016/s0165-6147(00)01639-4. Trends Pharmacol Sci. 2001. PMID: 11239577 Review.
-
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.Br J Pharmacol. 2014 Jun;171(11):2705-25. doi: 10.1111/bph.12598. Br J Pharmacol. 2014. PMID: 24467436 Free PMC article. Review.
-
The pharmacogenetics of NAT: structural aspects.Pharmacogenomics. 2002 Jan;3(1):19-30. doi: 10.1517/14622416.3.1.19. Pharmacogenomics. 2002. PMID: 11966400 Review.
-
Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.Adv Pharmacol. 2012;63:169-205. doi: 10.1016/B978-0-12-398339-8.00005-7. Adv Pharmacol. 2012. PMID: 22776642 Review.
Cited by
-
Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.Biochem J. 2003 Nov 1;375(Pt 3):593-602. doi: 10.1042/BJ20030812. Biochem J. 2003. PMID: 12904181 Free PMC article.
-
Berberine inhibits arylamine N-acetyltransferase activity and gene expression in Salmonella typhi.Curr Microbiol. 2005 Oct;51(4):255-61. doi: 10.1007/s00284-005-4569-7. Epub 2005 Aug 2. Curr Microbiol. 2005. PMID: 16086103
-
Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.Methods Mol Biol. 2021;2342:781-808. doi: 10.1007/978-1-0716-1554-6_29. Methods Mol Biol. 2021. PMID: 34272717
-
Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):377-400. doi: 10.1007/s10928-005-0001-y. J Pharmacokinet Pharmacodyn. 2005. PMID: 16320099 Clinical Trial.
-
Acetyl coenzyme A kinetic studies on N-acetylation of environmental carcinogens by human N-acetyltransferase 1 and its NAT1*14B variant.Front Pharmacol. 2022 Oct 28;13:931323. doi: 10.3389/fphar.2022.931323. eCollection 2022. Front Pharmacol. 2022. PMID: 36386142 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials